Postmenopausal osteoporosis
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: The aim of this study is to provide a thorough updated review of the diagnosis and treatment of postmenopausal osteoporosis. RECENT FINDINGS: There have been several important findings in the field of postmenopausal osteoporosis over the past 1-2 years. Fewer morphometric vertebral fractures were found in women treated for 6 years with zoledronic acid compared with those who stopped treatment after 3 years. Longer duration of bisphosphonate therapy is associated with a higher risk of atypical femur fractures. Combination therapy with teriparatide and denosumab appears to increase bone mineral density to a greater extent than either therapy alone in postmenopausal women at high risk for fracture. There are several novel therapies under investigation for the treatment of osteoporosis, which are in various stages of development. Nonadherence to osteoporosis therapies continues to be a major problem in clinical practice. SUMMARY: There are numerous effective pharmacologic treatment options for postmenopausal osteoporosis. Bisphosphonate drug holidays continue to be an area of significant debate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650 · cited 1×
“ONJ has been described in patients receiving chronic bisphosphonate therapy for treatment of osteoporosis but appears to be much more common in cancer patients receiving bisphosphonates in 10–12 times higher doses than those used to treat osteoporosis [34].”
Self-citationBlack, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Tang, B. M., Eslick, G. D., Nowson, C., Smith, C., & Bensoussan, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61342-7 · Cited by 1,248
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Self-citationBlack, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Screening for Osteoporosis: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-5-201103010-00307 · Cited by 436
Prentice, R. L., Pettinger, M. B., Jackson, R. D., Wactawski-Wende, J., LaCroix, A. Z., Anderson, G. L., Chlebowski, R. T., Manson, J. E., Van Horn, L., Vitolins, M. Z., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2224-2 · Cited by 295
Benefits and risks of bisphosphonate therapy for osteoporosis
Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1027 · Cited by 290
Cited by
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
“, abaloparatide, romosozumab, teriparatide), therapy with an antiresorptive agent, such as denosumab, bisphosphonates, or raloxifene, is recommended to prevent loss of BMD and fracture efficacy (222,224,337,339-345).”
Self-citationCamacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 478
Self-citationBioprinting and organ-on-chip applications towards personalized medicine for bone diseases
Arrigoni, C., Gilardi, M., Bersini, S., Candrian, C., & Moretti, M. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9741-5 · Cited by 68
Yoon, B.-H., Lee, Y., Oh, H. J., Kim, S. H., & Lee, Y.-K. (2019) · Journal of Bone Metabolism · doi:10.11005/jbm.2019.26.1.51 · Cited by 46
Metadata
- Authors
- Diab, D. L., & Watts, N. B.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2013-12
- Volume
- 20
- Issue
- 6
- Pages
- 501-509
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W4235699389
- Cited by
- 85
- References
- 11
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Postmenopausal osteoporosis. https://app.cochat.ai/papers/10.1097/01.med.0000436194.10599.94
- The paper
- Diab, D. L., & Watts, N. B. (2013). Postmenopausal osteoporosis. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/01.med.0000436194.10599.94
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.